[company_age]5.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]Lentitek is a biotechnology company based in Edinburgh, Scotland, that is focused on developing solutions to improve the production yield of viral vectors used in gene therapies and CAR-T therapies. The company's proprietary technology is based on a novel promoter that can significantly reduce vector genome splicing and payload breakthrough expression, leading to higher manufacturing yields and improved product potency. Lentitek's technology is easy to integrate into existing production methods and can be applied to both transient transfection and stable cell line production. The company is actively seeking application partners to exploit its technology and help bring these life-changing therapies to more people.[/description][ps]Lentitek offers a proprietary technology that can significantly improve the production yield of viral vectors used in gene therapies and CAR-T therapies.[/ps]